Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.
Yes, blood tests for neurodegenerative diseases could significantly increase demand for neurologists—but only if the healthcare system can actually produce more neurologists to handle the surge. Recent advances in blood biomarkers have made it possible to detect early signs of Alzheimer’s disease, Parkinson’s disease, and other brain conditions years before symptoms appear. A single blood test can now measure phosphorylated tau and amyloid beta levels with an accuracy that rivals expensive PET imaging scans, opening the door to widespread screening in primary care settings. If millions of people undergo these tests and thousands receive results suggesting early neurological disease, the demand for specialist evaluation would skyrocket.
The challenge is that the neurology workforce is already stretched thin. The United States currently faces a shortage of approximately 2,000 to 6,000 neurologists depending on the metric used, with wait times for appointments in some regions exceeding three months. Adding mass screening to this equation creates a fundamental mismatch: supply of neurologists cannot quickly expand to meet surge demand from early detection programs. Understanding whether blood tests will actually trigger an unsustainable flood of referrals requires examining the test results themselves, the current state of neurology practices, and what truly happens when a patient gets a positive result.
Table of Contents
- Can Blood Tests Actually Identify Brain Disease Early?
- The Math Behind Testing Demand and Specialist Referrals
- The Bottleneck: Understanding the Current Neurology Shortage
- What Happens After a Positive Blood Test? The Patient’s Journey
- The False Positive Problem and Overdiagnosis Risk
- Training Timelines and the Supply Reality
- Who Actually Needs Specialist Care After a Positive Blood Test?
- Frequently Asked Questions
Can Blood Tests Actually Identify Brain Disease Early?
Blood biomarker tests have evolved from experimental research tools to clinically validated diagnostics in less than a decade. Tests now measure phosphorylated tau, phosphorylated tau-181, amyloid beta-42, neurofilament light chain, and other proteins that accumulate in the brain during Alzheimer’s and Parkinson’s disease. A 2023 study published in JAMA Neurology showed that blood phosphorylated tau-181 levels could identify Alzheimer’s pathology with 95 percent accuracy compared to PET imaging, which costs $4,000 to $6,000 per scan. For comparison, a blood biomarker test costs between $150 and $500, making it feasible for routine screening during annual physical exams.
These tests detect biological changes that may happen 10 to 20 years before cognitive symptoms emerge. Someone might test positive for amyloid and tau accumulation at age 50 and remain cognitively normal until age 70—or never develop dementia symptoms at all. This creates a substantial pool of cognitively asymptomatic individuals with positive biomarkers, and each of these people represents a potential referral to a neurologist for risk assessment and monitoring. If primary care physicians adopt routine screening, even a 30 percent positive rate in screening populations would translate to millions of referrals annually.
The Math Behind Testing Demand and Specialist Referrals
The potential scale of new neurologist demand becomes clear when you map out a realistic screening scenario. The United States has approximately 330 million people. The Alzheimer’s Association estimates that 6.7 million Americans aged 65 and older currently have Alzheimer’s disease or related dementias, but research suggests that 25 to 30 percent of cognitively normal older adults have Alzheimer’s pathology visible on PET imaging. If blood tests enable screening to expand from high-risk populations to routine screening for all adults over 55, the number of positive results could easily reach 50 million people over five years.
Not all positive results will generate a referral to neurology, but many will. Conservative estimates suggest that 20 to 40 percent of people with positive blood biomarkers would be referred to a neurologist for specialized assessment, treatment discussion, and long-term monitoring. This could mean an additional 10 to 20 million referrals spread across the existing neurology workforce—a surge that would require doubling or tripling the number of neurologists within a decade. The current system simply does not have the capacity to absorb this increase, and there is no realistic timeline for training and licensing that many new specialists.
The Bottleneck: Understanding the Current Neurology Shortage
The United States faces a documented shortage of neurologists that predates blood biomarker testing. According to the Association of American Medical Colleges, the projected shortfall of neurologists by 2036 ranges from 4,000 to 6,000 depending on demand estimates. Some states, particularly rural areas and smaller metropolitan regions, have fewer than 5 neurologists per 100,000 residents, compared to the recommended minimum of 8 per 100,000.
patients in these regions already wait 6 to 12 weeks for appointments with a neurologist. The neurology shortage stems from multiple factors: the specialty takes 13 to 15 years to complete (four years of medical school plus 9 to 11 years of residency and fellowship training), the average annual salary for a neurologist is lower than for radiologists or cardiologists, and the specialty carries high rates of physician burnout related to complex patients with limited treatment options. Even if medical schools increased enrollment today, it would take until 2039 or 2040 before those physicians became practicing neurologists. The timing gap between blood test availability and neurologist supply is substantial and difficult to close through training alone.
What Happens After a Positive Blood Test? The Patient’s Journey
When someone receives a positive blood biomarker result, the typical next step is a referral to a neurologist, but the actual pathway depends on the patient’s cognitive status and symptoms. A cognitively normal 60-year-old with positive amyloid and tau levels might be offered participation in clinical trials, preventive therapy trials (such as anti-amyloid monoclonal antibodies), or a monitoring plan with annual neuropsychological testing. A 72-year-old with mild memory complaints and positive biomarkers might receive cognitive training recommendations, medication evaluation, and baseline neuroimaging. The visit itself often requires 60 to 90 minutes for detailed history, cognitive testing, and discussion of treatment options.
The workload per patient increases when neurologists must monitor multiple asymptomatic individuals with biomarker positivity. Unlike acute conditions that resolve, these patients typically require ongoing surveillance. Some neurologists now maintain registries of cognitively asymptomatic individuals with biomarker evidence of Alzheimer’s pathology, checking in annually or twice yearly. This fundamentally changes the neurology practice model from specialist-for-acute-problems to specialist-for-long-term-monitoring, which reduces the number of new patients any single neurologist can see. A neurologist managing 200 cognitively asymptomatic monitored patients plus their traditional acute and symptomatic caseload reaches capacity quickly.
The False Positive Problem and Overdiagnosis Risk
Not everyone with positive blood biomarkers will develop cognitive decline or dementia. Research from the Framingham Heart Study suggests that approximately 30 percent of cognitively normal older adults with Alzheimer’s pathology never progress to mild cognitive impairment or dementia during their remaining lifespan. This means that widespread screening could label millions of people with a disease that they may never experience, creating psychological burden and unnecessary specialist visits. A 58-year-old with positive tau levels and no cognitive symptoms might spend 30 years worrying about dementia, visiting neurologists repeatedly, and modifying life plans based on a risk that never materializes.
The false positive concept is complicated by the fact that biomarker positivity is not truly false—it reflects real pathological change in the brain. However, pathology and disease are not synonymous. The limitation is that current blood tests cannot predict with certainty which individuals will progress and which will remain stable. This uncertainty is precisely what drives demand for neurologist expertise; the specialist must see the patient to interpret the result in context of family history, lifestyle, cognition, and other factors. However, this also means that demand for neurologists could include many visits from individuals who do not actually need specialist intervention.
Training Timelines and the Supply Reality
Creating new neurologists cannot happen quickly. A physician who decides to become a neurologist today would complete medical school (4 years), internal medicine residency (3 years), neurology residency (3 years), and often subspecialty fellowship training (1 to 3 additional years). The total investment is 11 to 15 years before they can practice independently. Even if the number of neurology residency positions increased by 50 percent tomorrow, the system would not see significantly more practicing neurologists until 2040.
Medical schools also cannot simply expand enrollment without accreditation approval, faculty expansion, and clinical training site availability. The subspecialties within neurology, such as cognitive neurology and behavioral neurology (the specialists best suited to manage Alzheimer’s disease and dementia), require even longer training and are less attractive to trainees than more procedure-based specialties. Vascular neurology, which includes stroke treatment, is more appealing because procedures generate higher income and offer more acute, time-sensitive decision-making. Expanding the cognitive neurology workforce specifically would be even slower than expanding general neurology.
Who Actually Needs Specialist Care After a Positive Blood Test?
Not every person with a positive blood biomarker requires ongoing neurology care. Someone in their 40s with incidental biomarker positivity but no family history, no cognitive symptoms, and excellent baseline neurocognitive testing may benefit more from general preventive health measures and primary care monitoring than from specialist neurology visits. Primary care physicians with appropriate training could manage risk factor modification, cognitive monitoring via telephone or video, and referral to neurology only if symptoms develop or cognition declines on testing. The question of who truly needs a neurologist is critical to understanding whether blood test screening will overwhelm the specialty.
If neurologists can triage results and reserve their time for patients with symptoms, cognitive decline, or positive imaging findings, demand may remain manageable. However, if each positive blood test generates a referral and each positive referral results in an initial specialty visit plus annual monitoring, the system will break. Some health systems are experimenting with nurse coordinators and cognitive specialists who handle longitudinal monitoring of asymptomatic biomarker-positive individuals, reserving neurologists for diagnostic complexity and treatment decisions. This model could distribute the workload, but it requires infrastructure investment and training in currently understaffed regions.
- —
Frequently Asked Questions
How accurate are blood tests for Alzheimer’s disease?
Modern blood biomarker tests measure phosphorylated tau and amyloid beta with 95 to 98 percent accuracy compared to PET imaging and cerebrospinal fluid analysis. However, accuracy for predicting future cognitive decline is lower, around 70 to 85 percent, because not all individuals with biomarker positivity will develop symptoms.
Will my insurance cover blood biomarker testing?
Coverage varies widely. Medicare currently covers phosphorylated tau-181 testing for individuals with cognitive concerns, but does not cover routine screening in cognitively normal adults. Many commercial insurers follow similar patterns, requiring either symptoms or cognitive complaints before approving the test. This fragmentation means widespread screening adoption would depend on changes in insurance policy.
What should I do if I get a positive blood biomarker result?
Request a referral to a neurologist or cognitive specialist, but also ask your primary care doctor if neurology referral is truly necessary given your age, cognition, and family history. Some individuals benefit from enrollment in clinical trials of prevention therapies, while others may be better served by primary care monitoring plus annual cognitive screening.
How long do people wait to see a neurologist in the United States?
Wait times vary by region and urgency. For routine cognitive concerns, waits range from 4 to 12 weeks in urban areas and up to 6 months in rural regions. Urgent appointments for acute conditions are typically available within 1 to 2 weeks.
Can primary care doctors manage patients with positive blood biomarkers without specialist referral?
Yes, if the patient is cognitively normal and the primary care doctor has training in cognitive health screening and risk factor management. However, most primary care physicians currently lack specialized training in interpreting biomarker results and managing dementia prevention. —
